Review Article
Volume 6 Issue 3 - 2020
The Renewel of Natural Product Used for Drug Discovery in the Genomic Era
Mehtab Muhammad Aslam1*, Noor-ul-Ain2, Peng Gang3 and Yan Fang3
1Center for Plant Water-Use and Nutrition Regulation, College of Life Sciences, Joint International Research Laboratory of Water and Nutrient in Cops, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China
2FAFU and UIUC-SIB Joint Center for Genomics and Biotechnology, College of Agriculture, Fujian Agriculture and Forestry University, Fuzhou, China
3Horticulture Plant Biology and Metabolomics Center, Haixia Institute of Science and Technology (HIST), Fujian Agriculture and Forestry University, Fuzhou, Fujian, China
*Corresponding Author: Mehtab Muhammad Aslam, Center for Plant Water-Use and Nutrition Regulation, College of Life Sciences, Joint International Research Laboratory of Water and Nutrient in Cops, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.
Received: December 23, 2019; Published: February 24, 2020




Abstract

Natural products are considered as main source for drug innovation. The tiny molecules having multiple functions made by animals, plants and microbial living forms are well-known as natural products and have outlined the basis of a lot of our present pharmacopeia. Up to 70% of all drug or medications available today have a motivation from nature. Therefore, their utilization has reduced in the previous two decades, to a limited extent due to the reason of specialized restriction to screening of natural products in high-throughput assay, that examines against sub-atomic molecular targets. As an outcome of the unbelievable significance of these natural products, both regarding their life saving effects and financial value, the life forms that create these constituents likewise have organized public worth. In this review methodologies for screening of natural products that tackle the current specialized advances that have decreased these limitations, additionally evaluate the utilization of genomic and metabolomics methods to deal with enlarge conventional techniques for reviewing natural products, and mention current example of natural products in antimicrobial medication or drug innovation and as inhibitors of protein to protein interactions. The developing appraisal for functional test and phenotypic screens may additionally add to a renovation of interest towards natural products for novel drug discovery. Understanding the estimation of biodiversity has given new conflicts for protection and preservation activities and takes into consideration distinctive confirmation that the overall population both admits and supports drug utilization and discovery. Different screening approaches are being created to enhance the simplicity with which natural products can be utilized as a part of drug innovation conflicts, and information mining and effective screening methods are additionally being connected to databases of natural items. It is trusted that the more proficient and viable use of natural products will enhance the drug innovation process.

Keywords: Natural Products; Drug Innovation; Biodiversity; Pharmacopeia; Screening Approaches; High Throughput Assay

References

  1. Newman DJ and Cragg GM. “Natural products as sources of new drugs over the 30 years from 1981 to 2010”. Journal of Natural Products 75 (2012): 311-335.
  2. Harvey AL., et al. “The re-emergence of natural products for drug discovery in the genomics era”. Nature reviews Drug Discovery 14 (2015): 111-129.
  3. Carter GT. “Natural products and Pharma 2011: Strategic changes spur new opportunities”. Natural Product Reports 28 (2011): 1783-1789.
  4. Cragg GM and Newman DJ. “Natural products: a continuing source of novel drug leads”. Biochimica et Biophysica Acta (BBA)-General Subjects 1830 (2013): 3670-3695.
  5. Butler MS., et al. “Antibiotics in the clinical pipeline in 2013”. The Journal of antibiotics 66 (2013): 571-591.
  6. Drewry DH and Macarron R. “Enhancements of screening collections to address areas of unmet medical need: an industry perspective”. Current opinion in Chemical Biology 14 (2010): 289-298.
  7. May BH., et al. “Collections of traditional Chinese medical literature as resources for systematic searches”. The Journal of Alternative and Complementary Medicine 18 (2012): 1101-1107.
  8. Wess G., et al. “Medicinal chemistry: challenges and opportunities”. Angewandte Chemie International Edition 40 (2001): 3341-3350.
  9. Oprea TI. “Property distribution of drug-related chemical databases”. Journal of Computer-Aided Molecular Design 14 (2000): 251-264.
  10. Wetzel S., et al. “Biology‐oriented synthesis”. Angewandte Chemie International Edition 50 (2011): 10800-10826.
  11. Bauer RA., et al. “Expanding the range of ‘druggable’targets with natural product-based libraries: an academic perspective”. Current Opinion in Chemical Biology 14 (2010): 308-314.
  12. Grabowski K., et al. “Scaffold diversity of natural products: inspiration for combinatorial library design”. Natural Product Reports 25 (2008): 892-904.
  13. Rosén J., et al. “Novel chemical space exploration via natural products”. Journal of Medicinal Chemistry 52 (2009): 1953-1962.
  14. Kellenberger E., et al. “Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs”. Natural Product Reports 28 (2011): 1483-1492.
  15. Fraser PD., et al. “Application of high‐performance liquid chromatography with photodiode array detection to the metabolic profiling of plant isoprenoids”. The Plant Journal 24 (2000): 551-558.
  16. Viegelmann C., et al. “Metabolomic profiling and genomic study of a marine sponge-associated Streptomyces sp”. Marine Drugs 12 (2014): 3323-3351.
  17. Hur M., et al. “A global approach to analysis and interpretation of metabolic data for plant natural product discovery”. Natural Product Reports 30 (2013): 565-583.
  18. Gray AI., et al. “Natural products isolation in modern drug discovery programs”. In Natural Products Isolation Springer (2012): 515-534.
  19. Krizevski R., et al. “Benzaldehyde is a precursor of phenylpropylamino alkaloids as revealed by targeted metabolic profiling and comparative biochemical analyses in Ephedra spp”. Phytochemistry 81 (2012): 71-79.
  20. Buenafe OE., et al. “Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models”. ACS Chemical Neuroscience 4 (2013): 1479-1487.
  21. Wang X., et al. “Differential cardioprotective effects of salvianolic acid and tanshinone on acute myocardial infarction are mediated by unique signaling pathways”. Journal of Ethnopharmacology 135 (2011): 662-671.
  22. Narvi E., et al. “Altered TUBB3 expression contributes to the epothilone response of mitotic cells”. British Journal of Cancer 108 (2013): 82-90.
  23. Alvarez RH., et al. “Ixabepilone for the treatment of breast cancer”. Annals of medicine 43 (2011): 477-486.
  24. Oßwald C., et al. “Modular construction of a functional artificial epothilone polyketide pathway”. ACS Synthetic Biology 3 (2014): 759-772.
  25. Brierley I. “Macrolide-induced ribosomal frameshifting: a new route to antibiotic resistance”. Molecular Cell 52 (2013): 613-615.
  26. Berthier E., et al. “Low-volume toolbox for the discovery of immunosuppressive fungal secondary metabolites”. PLoS Pathogens 9 (2013).
  27. Chen L., et al. “Genomics-driven discovery of the pneumocandin biosynthetic gene cluster in the fungus Glarea lozoyensis”. BMC Genomics 14 (2013): 339.
  28. Neubig RR and Siderovski DP. “Regulators of G-protein signalling as new central nervous system drug targets”. Nature Reviews Drug Discovery 1 (2002): 187-197.
  29. Azzi M., et al. “Corrosion performance and mechanical stability of 316L/DLC coating system: Role of interlayers”. Surface and Coatings Technology 204 (2010): 3986-3994.
  30. Richardson B., et al. “Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs”. Nature 316 (1985): 126-131.
  31. Lipinski CA. “Drug-like properties and the causes of poor solubility and poor permeability”. Journal of Pharmacological and Toxicological Methods 44 (2000): 235-249.
  32. Hopkins AL., et al. “Ligand efficiency: a useful metric for lead selection”. Drug Discovery Today 9 (2004): 430-431.
  33. Ashoor LA and Qusti SY. “Potential interactions between Cinnamon and Metformin treatment in diabetic rats”. Biosciences Biotechnology Research Asia 7 (2016): 607-616.
  34. Ji HY., et al. “Evaluation of DA-9801, a new herbal drug for diabetic neuropathy, on metabolism-mediated interaction”. Archives of Pharmacal Research 36 (2013): 1-5.
  35. MacGowan A and Albur M. “Frontline antibiotic therapy”. Clinical Medicine 13 (2013): 263.
  36. Higueruelo AP., et al. “Protein–protein interactions as druggable targets: recent technological advances”. Current Opinion in Pharmacology 13 (2013) 791-796.
  37. Khoo KH., et al. “Drugging the p53 pathway: understanding the route to clinical efficacy”. Nature Reviews Drug Discovery 13 (2014): 217-236.
  38. Jones RJ., et al. “The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1”. Journal of Pharmacology and Experimental Therapeutics 346 (2013): 381-392.
  39. Kaida D., et al. “Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA”. Nature Chemical Biology 3 (2007): 576.
  40. Shen C-y., et al. “Development and characterization of an orodispersible film containing drug nanoparticles”. European Journal of Pharmaceutics and Biopharmaceutics 85 (2013): 1348-1356.
  41. Strovel J., et al. “Early drug discovery and development guidelines: for academic researchers, collaborators, and start-up companies”. In Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences (2016).
  42. Van Kesteren C., et al. “Yondelis®(trabectedin, ET-743): the development of an anticancer agent of marine origin”. Anti-cancer Drugs 14 (2003): 487-502.
  43. McWilliams., et al. “North from Mexico: The Spanish-Speaking People of the United States: The Spanish-Speaking People of the United States ABC-CLIO”. (2016).
  44. Jordá EG. “Nobel Science Prizes”. Clinical and Translational Oncology 11 (2009): 708.
  45. Swinney D. “Phenotypic vs. target‐based drug discovery for first‐in‐class medicines”. Clinical Pharmacology and Therapeutics 93 (2013): 299-301.
  46. Kunkel EJ., et al. “Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models”. Assay and Drug Development Technologies 2 (2004): 431-442.
  47. Naman CB., et al. “Modern natural products drug discovery and its relevance to biodiversity conservation”. In Microbial Resources (2017): 103-120.
  48. Carter GT. “NP/MS since 1970: from the basement to the bench top”. Natural Product Reports 31 (2014): 711-717.
Citation: Mehtab Muhammad Aslam., et al. “The Renewel of Natural Product Used for Drug Discovery in the Genomic Era”. EC Agriculture 6.3 (2020): 01-15.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


July Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the July issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before July 15, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.